What to expect when taking Mounjaro for weight loss

Obesity is a chronic metabolic condition, and not a matter of willpower. It affects how the body regulates appetite, blood sugar, and energy, and it increases the risk of long-term health problems such as heart disease and type 2 diabetes. For many people, repeated attempts at diet and exercise alone aren’t enough because the body actively resists weight loss.

That’s why newer medical interventions focus on biology, not blame. Tirzepatide, the active ingredient in Mounjaro, works with natural gut hormones involved in hunger and fullness. By helping reduce appetite and slow digestion, it supports gradual, sustained weight loss as part of a structured, clinician-led approach to obesity care.¹ 

How Mounjaro works for weight loss

Tirzepatide works by acting on two natural gut hormones, GLP-1 and GIP, that help control blood sugar and appetite. Together, these signals help the body release insulin more effectively after meals, reduce hunger, and support feelings of fullness.¹

Because it stays active in the body for several days, it’s taken just once a week. In clinical studies, people taking tirzepatide lost a significant amount of weight over time, alongside improvements in markers linked to insulin sensitivity and metabolic health.²

What results can you expect overall?

Most people don’t lose a large amount of weight in the first week or two. Early changes are often subtle as your body adjusts to the medication and appetite begins to settle. Often people notice reduced hunger first, before the scales move in a meaningful way.²

Over the first few months, weight loss usually becomes more noticeable and more consistent. In clinical studies, the majority of people taking tirzepatide lost at least 5% of their starting weight over time, with steady progress rather than rapid drops. This slower pace is expected and is generally safer and easier to maintain.²

As treatment continues and doses are gradually increased, weight loss tends to build. By around a year to a year and a half, people taking tirzepatide lost, on average:²

• Around 15% of their starting weight on lower maintenance doses

• Around 19-21% of their starting weight on higher maintenance doses

Importantly, many people achieved substantial results, with roughly half of those on higher doses losing 20% or more of their body weight. Alongside weight loss, improvements were seen in markers linked to heart and metabolic health.²

Common Mounjaro side effects

Like other appetite-regulating medications, Mounjaro can cause side effects, particularly as your body adjusts. Studies show that most people experience mild effects, if any, and they tend to be temporary, easing as treatment continues or once a dose has settled.

The most commonly reported side effects are digestive and include:^1,2

• Nausea

• Diarrhoea

• Constipation

• Vomiting or acid reflux

Less commonly, some people may notice:^1,2

• A faster heart rate

• Injection-site reactions such as redness or irritation

• Symptoms linked to dehydration if fluid intake is low

Rare but important side effects such as pancreatitis, gallbladder issues, or changes in blood sugar are uncommon and are monitored closely by clinicians. You’ll always be advised on what to watch for and when to seek medical advice.

Who Mounjaro is (and isn’t) suitable for

Who can access Mounjaro depends a lot on whether you’re going through the NHS or a private provider.

On the NHS, access to Mounjaro follows strict NICE guidance and is being rolled out in phases. In practice, this means treatment is currently limited to people with more severe obesity and multiple weight-related health conditions, and waiting times can be long.

At present or over the next few years, NHS eligibility generally requires:³

• A BMI of 35 kg/m² or higher, plus at least one weight-related condition, such as high blood pressure, abnormal cholesterol, sleep apnoea, cardiovascular disease, or type 2 diabetes

• In many cases, a BMI of 40 kg/m² or higher, often alongside multiple weight-related conditions

• Lower BMI thresholds (by around 2.5 kg/m²) apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds

Even if someone meets the criteria, NHS access may be delayed due to phased funding and service capacity. Treatment is also reviewed closely, and continuation usually depends on achieving meaningful weight loss (typically at least 5% within six months at the highest tolerated dose).

Private providers, including Numan, can offer access sooner because eligibility isn’t constrained by NHS funding thresholds. Instead, decisions are made on clinical appropriateness and safety, guided by national and international standards.

With Numan, Mounjaro may be suitable if you:

• Are 18 years or older, and

• Have a BMI of 30 kg/m² or above, or

• Have a BMI of 27 kg/m² or above with at least one weight-related condition (such as high blood pressure, high cholesterol, insulin resistance, or pre-diabetes), and

• Complete a medical assessment reviewed by a qualified prescriber

This approach recognises that earlier intervention can reduce long-term health risks, rather than waiting until obesity becomes more severe.

Who Mounjaro isn’t suitable for

Mounjaro isn’t appropriate for everyone. It may not be suitable if you:

• Don’t meet BMI or clinical criteria

• Have certain medical conditions or medication interactions

• Are pregnant, breastfeeding, or planning pregnancy

• Are seeking a short-term or cosmetic weight-loss solution

The numan take

By working with the body’s appetite and metabolic systems, Mounjaro supports steady, clinically meaningful weight loss when combined with proper medical oversight and lifestyle support. The key is suitability, safety, and long-term thinking, which is why treatment should always start with a thorough assessment and ongoing clinician care, not guesswork or pressure to rush results.

References

1. Farzam K, Patel P. Tirzepatide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.

2. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.

3. Tirzepatide for managing overweight and obesity. NICE. [accessed 29 Jan 2026] Available from: https://www.nice.org.uk/guidance/ta1026